Table 5.

Difference in lab tests for the two groups.

	Adalimumab group	Total	Control group	Total	P-Value
WBC before adalimumab	7.7(4.21–10.58)	25	6.48(4.62–9.96)	25	0.82
WCB 3 days after adalimumab	9.29 ± 3.79	14	10.8 ± 5.1	14	0.38
D-Dimer before adalimumab	806(405–1490)	25	460(308–720)	21	0.059
D-Dimer 3 days after adalimumab	888(435.5–1619)	18	405(264.25–1086.75)	16	0.03
Ferritin before adalimumab	900.5(463.75–1373.75)	28	523 (295–1030)	31	0.18
Ferritin after 3 days after adalimumab	1273.88 ± 561.29	18	689.81 ± 567.91	16	0.005
CRP before adalimumab	70(54–81)	31	56(38–73)	34	0.053
CRP 3 days after adalimumab	12(4.75–22.25)	30	22 (11–42)	23	0.025
IL-6 before adalimumab	22.25 ± 12.01	29	16.1 ± 8.96	33	0.02
IL-6 3 days after adalimumab	17.8 ± 10.15	21	19.1 ± 11.51	17	0.71
TNF-α before adalimumab	6.5 (5.5–10.1)	27	7.45(6.02–10.45)	26	0.68
TNF-α 3 days after adalimumab	6.9 (5.15–11.4)	20	6.8 (5.9–10.2)	21	0.91

Data are presented as Mean ± SD; CRP: C-Reactive Protein; IL-6: Interleukin-6